AAVantgarde presents safety data of the first two subjects dosed in the LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1B December 9, 2024
Be Biopharma Unveils BeCoMe-9 Trial and Presents on Versatile B Cell Medicines Platform December 9, 2024
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years December 6, 2024
Senior Pharma and Biotech Leaders to Gather the Weekend Immediately Prior to JP Morgan Healthcare Conference for 2 Day Networking Forum, San Francisco CEO, Hosted by Longwood Healthcare Leaders December 5, 2024
AAVantgarde Bio Announces FDA Orphan Drug Designation for AAVB-081 for the Treatment of Usher Syndrome Type 1B Retinitis Pigmentosa December 2, 2024
Rectify Pharma Presents Preclinical Data Supporting Development of Lead Candidate RTY-694 November 19, 2024
